{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 28 of 92', 'CR845-CLIN3102', 'complete the NRS worksheets (either at home or in the dialysis unit, as required) at a', 'similar time of day around the normal start time of their dialysis.', 'Patients will also be trained on other itch-related patient-reported outcome (PRO) and', 'patient health assessment worksheets during the Run-in Period or on Day 1 of the', 'Double-blind Treatment Period.', 'A Structured Safety Evaluation will be performed during the Run-in Period (preferably', 'on Wednesday/Thursday). The Structured Safety Evaluation is performed by study staff', 'using a list of specific signs/symptoms (eg, mental status change, falls, gait disturbance).', '6.1.1.3', 'Double-blind Treatment Period', 'If patients continue to meet all inclusion and no exclusion criteria at the end of the 7-day', 'Run-in Period, they will be randomized into the Double-blind Treatment Period in a', '1:1 ratio to receive either IV CR845 0.5 mcg/kg or placebo. Patients will be stratified', 'according to their use or non-use of concomitant medications to treat their itch during the', 'week prior to randomization (Run-in Period) as well as the presence or absence of', 'specific medical conditions.', 'Day 1 of the Double-blind Treatment Period will be defined as the day of administration', 'of the first dose of study drug and will occur on the first dialysis session day of the first', 'treatment week (ie, Monday for patients on a Monday-Wednesday-Friday dialysis', 'schedule or Tuesday for patients on a Tuesday-Thursday-Saturday dialysis schedule).', 'Patients will be administered CR845 or matched placebo as an IV bolus after the end of', 'each dialysis session during the 12-week Double-blind Treatment Period so that each', 'patient will receive CR845 or placebo 3 times weekly for a total of up to 36 doses.', 'During the Double-blind Treatment Period, patients will continue to report their Worst', 'Itching Intensity NRS score on a daily basis, covering the previous 24 hours. In addition,', 'during selected study visits, they will complete other PRO measures (Skindex-10 Scale,', '5-D Itch Scale, and Patient Global Impression of Change). Patients will be instructed to', 'record patient-reported outcome measurements, including Worst Itching Intensity NRS', 'scores, at a similar time of day, whether in the dialysis unit (on dialysis days) or at home', '(on non-dialysis days).', 'Blood samples for inflammatory biomarkers will be collected for all randomized patients', 'prior to dialysis on Day 1 and prior to the last dialysis at the End-of-Treatment Visit for', 'the Double-blind Treatment Period (Day 85).', 'Clinical laboratory tests and vital signs will be monitored periodically, and adverse', 'events and concomitant medications will be continuously recorded starting at the', 'Screening Visit until the end of the Discontinuation Period or Early Termination Visit.', 'Electrocardiograms (ECGs) will be monitored at Screening Visit and Day 85 or Early', 'Termination Visit.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 30 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 29 of 92', 'CR845-CLIN3102', 'The number and reason(s) for missed dialysis as well as the use of antipruritic', 'medications, iron, and erythropoiesis-stimulating agents (ESAs) will be recorded', 'throughout the study.', 'A Structured Safety Evaluation will be performed weekly (preferably on', 'Wednesday/Thursday) during the Double-blind Treatment Period. The Structured Safety', 'Evaluation is performed by study staff using a list of specific signs/symptoms (eg, mental', 'status change, falls, gait disturbance).', '6.1.1.4', 'Double-blind Discontinuation Period', 'The Double-blind Treatment Period will be followed by a 2-week Discontinuation', 'Period, during which no study drug will be administered and patients will be monitored', 'for potential physical dependence, as follows:', 'Daily patient completion of the Short Opiate Withdrawal Scale', '(ShOWS-Gossop 1990) (paper worksheet to be filled by each patient at home on', 'nondialysis days and at the dialysis unit on dialysis days at similar time of the day', 'for a given patient) (see worksheet in Appendix 6, Section 14.6)', 'Completion of an Objective Opiate Withdrawal Scale (OOWS) worksheet', '(Handelsman 1987) by a trained observer at each dialysis visit (ie, 3 times a week)', '(see worksheet in Appendix 7, Section 14.7) (training of observer will be', 'recorded)', 'Recording of adverse events, medication used, body temperature, and vital signs', 'at each dialysis visit.', 'Measurements will be taken starting at the end of the Treatment Period (Day 85) and then', 'at each dialysis visit for up to 2 weeks following study drug discontinuation until Day 98', '(Table 2).', 'During this Discontinuation Period, at each dialysis visit, patients will be asked to', 'continue to report their daily Worst Itching Intensity NRS score over the previous', '24 hours. In order to minimize bias, the OOWS and ShOWS will be introduced to the', 'patients as health-assessment scales.', 'On the day of a dialysis visit, the OOWS and the ShOWS will be completed during the', 'first hour (+1-hour window allowed) of dialysis so that dialysis-associated patient fatigue', 'should minimally interfere with the completion of the scales. Double-blind study drug', 'treatment assignment will remain blinded throughout the course of the Discontinuation', 'Period. For patients who withdraw from the Double-blind Treatment Period early, every', 'attempt will be made to conduct the 2-week Discontinuation Period.', 'A Structured Safety Evaluation will be performed weekly (preferably on', 'Wednesday/Thursday) during the Discontinuation Period. The Structured Safety', 'Evaluation is performed by study staff using a list of specific signs/symptoms (eg, mental', 'status change, falls, gait disturbance).', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 31 of 95']\n\n###\n\n", "completion": "END"}